Eyenovia, Inc. (EYEN)
NASDAQ: EYEN · Real-Time Price · USD
0.0346
-0.0003 (-0.86%)
At close: Jan 31, 2025, 4:00 PM
0.0350
+0.0004 (1.16%)
After-hours: Jan 31, 2025, 7:47 PM EST
Eyenovia Revenue
Eyenovia had revenue of $1.63K in the quarter ending September 30, 2024, with 35.64% growth. This brings the company's revenue in the last twelve months to $31.83K, up 2,557.10% year-over-year. In the year 2023, Eyenovia had annual revenue of $3.79K.
Revenue (ttm)
$31.83K
Revenue Growth
+2,557.10%
P/S Ratio
59.55
Revenue / Employee
$558
Employees
57
Market Cap
3.86M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 63.17B |
AbbVie | 56.33B |
Novartis AG | 51.72B |
AstraZeneca | 51.21B |
Thermo Fisher Scientific | 42.88B |
Abbott Laboratories | 41.95B |
EYEN News
- 4 days ago - Eyenovia Announces 1-for-80 Reverse Stock Split - GlobeNewsWire
- 17 days ago - Eyenovia Announces Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend Eyenovia Stockholders Vote “FOR” Proposed Reverse Stock Split at Upcoming Special Meeting of Stockholders - GlobeNewsWire
- 26 days ago - Eyenovia Engages Chardan as Advisor for Review of Strategic Alternatives - GlobeNewsWire
- 2 months ago - Eyenovia, Inc. Announces Pricing of $1.9 Million Registered Direct Offering - GlobeNewsWire
- 2 months ago - Eyenovia Provides Update on Restructuring Efforts - GlobeNewsWire
- 2 months ago - Eyenovia Stock Sinks As Pivotal Trial Fails To Hit Primary Efficacy Goal, Analyst Downgrades Due To Limited Capital And Near Term Upside From Pipeline - Benzinga
- 2 months ago - Eyenovia to discontinue late-stage study for eye drug - Reuters
- 2 months ago - Eyenovia Provides Update on Phase 3 CHAPERONE Study - GlobeNewsWire